ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ESSA Pharma Inc. (EPIX) presented preclinical data on its androgen receptor (AR) N-terminal domain degraders, ANITAC™, at the AACR Annual Meeting 2022.

Rhea-AI Summary

ESSA Pharma Inc. (EPIX) presented preclinical data on its androgen receptor (AR) N-terminal domain degraders, ANITAC™, at the AACR Annual Meeting 2022. The degraders effectively suppressed AR transcriptional activity and reduced prostate cancer cell viability in castration-resistant prostate cancer (CRPC) models. The data highlighted the ability of ANITAC™ to degrade various forms of AR expressed in CRPC patients. This innovative approach targets a significant challenge in treating advanced prostate cancer, where patients often develop resistance to existing therapies.

Positive

• Successful presentation of preclinical data demonstrating ANITAC™'s efficacy in degrading AR.
• ANITAC™ showed potential to inhibit AR activity in CRPC models, addressing a critical treatment need.
• Data presentation at a notable conference, enhancing visibility in the oncology field.

Negative

• None.

Argus Session date unavailable

+3.19% session move Open Argus

Details

News Market Reaction – EPIX

The recorded move for EPIX in the trading session of this news was +3.19%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders

ANITen bAsed Chimera (ANITAC™) degraders degrade full length, mutant and splice variant forms of AR that are expressed in CRPC patients

Orally bioavailable ANITAC degraders show robust functional activity in cellular models including inhibition of AR transcriptional activity and cell viability

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 8, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it will present preclinical data for its first generation of androgen receptor (AR) N-terminal domain degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting. The ANITen bAsed Chimera (ANITAC™) degraders suppressed AR transcriptional activity and decreased the viability of prostate cancer cells in castration-resistant prostate cancer (CRPC) preclinical models. ANITAC degraders degraded full length, mutant and splice variant forms of AR that are expressed in CRPC patients.

Poster presentation details are as follows: 

Title: Androgen receptor (AR) N-Terminal Domain degraders can degrade AR full length and AR splice variants in CRPC preclinical models
Authors: Nan Hyung Hong, et al.
Abstract Number: 429 
Session Title: Protein Degraders and Proteasome Inhibitors
Session Date and Time: Sunday, April 10, 2022 | 1:30 p.m. - 5:00 p.m. ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 26

The e-poster will be available to 2022 AACR Annual Meeting attendees and on the Company's website at www.essapharma.com on April 8, 2022, at 1:00 p.m. ET.

About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.

About Prostate Cancer
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone can lead to mCRPC. The treatment of mCRPC patients has evolved rapidly over the past ten years. Despite these advances, many patients with mCRPC fail or develop resistance to existing treatments, leading to continued disease progression and limited survival rates.

View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-present-preclinical-data-for-its-first-generation-of-androgen-receptor-n-terminal-domain-degraders-at-the-2022-american-association-for-cancer-research-aacr-annual-meeting-301498244.html

SOURCE ESSA Pharma Inc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the significance of ESSA Pharma's ANITAC™ degraders?

ANITAC™ degraders show promise in effectively targeting and degrading androgen receptors in castration-resistant prostate cancer, potentially offering new treatment avenues.

When and where was the data on ANITAC™ presented?

The data was presented at the AACR Annual Meeting on April 10, 2022, in New Orleans.

What were the findings related to ANITAC™'s effectiveness?

The preclinical data indicated that ANITAC™ effectively suppressed AR transcriptional activity and reduced the viability of prostate cancer cells.

How does ANITAC™ address treatment challenges in prostate cancer?

ANITAC™ targets full-length and variant forms of androgen receptors, which are often associated with treatment resistance in advanced prostate cancer.

What is the potential market impact of ESSA Pharma's research?

If successful, ANITAC™ could provide an innovative treatment option for patients with castration-resistant prostate cancer, addressing a significant unmet need and potentially increasing ESSA's market valuation.